Skip to main content

Scar

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Galderma
GaldermaTX - Dallas
1 program
1
Botulinum ToxinsPhase 2/31 trial
Active Trials
NCT03887377Completed22Est. Dec 2024
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Botulinum Toxin Type APhase 21 trial
Active Trials
NCT01177358Completed40Est. May 2016
Innovo Therapeutics
Innovo TherapeuticsCA - San Diego
1 program
1
INV-001Phase 21 trial
Active Trials
NCT05838833Unknown75Est. Jun 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GaldermaBotulinum Toxins
Innovo TherapeuticsINV-001
AbbVieBotulinum Toxin Type A

Clinical Trials (3)

Total enrollment: 137 patients across 3 trials

NCT03887377GaldermaBotulinum Toxins

The Efficacy and Molecular Mechanism of Botulinum Toxin in the Reduction of Breast Reduction Mammoplasty Scar Formation

Start: Jun 2019Est. completion: Dec 202422 patients
Phase 2/3Completed

Ointment to Prevent Scar After Thyroidectomy

Start: Feb 2023Est. completion: Jun 202475 patients
Phase 2Unknown
NCT01177358AbbVieBotulinum Toxin Type A

Botox in the Healing of Surgical Wounds of the Neck

Start: May 2010Est. completion: May 201640 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.